ARKRAY USA, a leader in diabetes care products, announced the company has been selected as a contracted supplier for the 340B prime vendor program, managed by Apexus.
The 340B program provides discounted drugs and medical supplies to qualifying healthcare facilities to help vulnerable patients gain access to drugs that help them manage their disease state.
The Blood Glucose Monitoring Systems (BGMS) that ARKRAY will be providing to the 340B program includes the GLUCOCARD® Expression™, an audio-enabled, auto-code BGMS that includes bilingual voice features for hearing a test result; and the GLUCOCARD® Shine, with auto-coding, indicators for strip expiration date and hypoglycemia, an LCD backlit screen, and pre- and post-meal averaging to differentiate glucose levels before and after meals.
"ARKRAY’s accurate, reliable and easy-to-use diabetes management products help patients of 340B hospitals and clinics live healthier lifestyles and lower healthcare costs," said ARKRAY USA President Jonathan Chapman. "In addition to our low-cost diabetes supplies, we provide wellness materials and continuing education at no charge, allowing providers to stretch their resources to serve more low-income and uninsured patients."
The ability to accurately measure glucose levels in blood is essential for people afflicted with diabetes so they can effectively manage the disease, according to the American Diabetes Association (ADA).
Diabetes, or diabetes mellitus, is a metabolic type of disease in which affected people have high blood glucose (blood sugar), either because insulin production is inadequate (Type 2), or because the islet cells in the pancreas no longer produce insulin (Type 1, sometimes referred to as juvenile diabetes).
Left untreated, diabetes can cause liver failure, cardiovascular complications and blindness. The ADA estimates that more than 30 million Americans suffer from either Type 1 or Type 2 diabetes and that 25.9% of Americans 65 years of age or greater will develop diabetes.